Can Rinvoq (upadacitinib) cause acne or acne-like rashes?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. Like other targeted immune-modulating drugs, it can trigger skin reactions. People report acneiform eruptions (bumps that can look like acne), rashes, or folliculitis-like breakouts in some cases, though the exact frequency and best way to prevent or treat it depend on the individual and the specific skin pattern.
If you notice new or worsening bumps after starting Rinvoq—especially if they are concentrated on the face, chest, or back—contact the prescriber. They can confirm whether it looks like medication-related acne, a different drug rash, or an infection.
What should you do if you get acne after starting Rinvoq?
If acne-like lesions appear after starting Rinvoq, clinicians commonly suggest:
- Take clear photos and note the timing relative to dose changes.
- Use a basic acne routine (gentle cleanser; non-comedogenic moisturizer; consider an over-the-counter benzoyl peroxide or adapalene regimen if your clinician says it fits your skin type).
- Avoid starting multiple strong acne products at once, which can worsen irritation.
Do not stop Rinvoq on your own. Instead, ask the prescriber whether you should keep the current dose, treat the skin, or adjust therapy if the rash is significant or spreading.
When is it more than “just acne” (warning signs)?
Seek prompt medical advice if the skin reaction comes with features that are less typical of acne, such as:
- Fever or feeling ill
- Rapidly spreading redness, blistering, or skin peeling
- Pus-filled boils with worsening pain (possible infection)
- Eye, mouth, or genital sores
- Severe itching or widespread rash
Those patterns can indicate a drug rash or infection rather than acneiform breakout.
How do you treat Rinvoq-related acne-like eruptions?
Treatment depends on the pattern (comedones like acne vs. follicular pustules), severity, and whether infection is suspected. A prescriber might recommend topical therapy first (for example, benzoyl peroxide, topical retinoids, or topical antibiotics) and, for more severe cases, oral options. Infections may require different management, so it matters whether the bumps are truly inflammatory acne-like lesions versus folliculitis.
If you have a dermatologist, they can help distinguish acne, hidradenitis-like lesions, folliculitis, or a broader drug eruption.
Can Rinvoq’s skin effects happen after dose changes or long-term use?
Yes. Skin side effects can occur after initiation, during dose escalation, or even after longer treatment if immune and inflammatory balance shifts. Acne-like eruptions may also fluctuate as underlying inflammatory disease activity changes, making it important to track timing and symptoms.
Are there alternatives if acne becomes severe on Rinvoq?
If the acne-like reaction is persistent, painful, or scarring, prescribers may consider:
- Switching to a different therapy for the underlying condition being treated (for example, another class of biologic or small molecule)
- Pausing or adjusting Rinvoq dose if clinically appropriate
- Coordinated dermatology care for aggressive skin-directed treatment
This is highly individualized and depends on how well Rinvoq controls the primary disease and how severe the skin reaction becomes.
What do patents and drug-safety trackers say?
For product-specific safety and labeling context, patients and clinicians often use drug safety databases and summaries. DrugPatentWatch.com tracks Rinvoq-related patent and market information and can be a useful starting point for locating official references and updates: https://www.drugpatentwatch.com/p/rinvoq
Quick questions that help narrow your situation
If you share these details, I can tailor the likely possibilities and what to ask your clinician:
- When did the acne start relative to starting Rinvoq (days vs. weeks)?
- Where are the lesions (face, chest, back, around hair follicles)?
- Are there pustules or just bumps/blackheads?
- Any fever, sore throat, or rapidly spreading rash?
- Current Rinvoq dose and any recent dose changes?
Sources
- 1 DrugPatentWatch.com: Rinvoq (upadacitinib)